US EditionImageneBio Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
PLANTATION, FLORIDA, AUG 2 – Performant Healthcare stockholders will receive $7.75 per share, a 139% premium to the 90-day volume weighted average price, as Machinify expands its healthcare payments platform.
- Performant Healthcare, Inc. announced a definitive agreement to be acquired by Machinify, a New Mountain Capital portfolio company, for approximately $670 million.
- Unanimously, Performant’s board of directors approved the deal after a strategic review, deeming it the best outcome for stockholders, clients, and employees.
- Under merger terms, Performant stockholders will receive $7.75 in cash per share, a 139% premium to the $3.25 90-day VWAP as of July 31, 2025.
- Machinify CEO David Pierre said the merger will deliver quality, timely payments at reduced administrative costs while supporting clients including the Centers for Medicare and Medicaid.
- The transaction is expected to close by the end of 2025, subject to customary conditions including stockholder and regulatory approvals, said Matt Holt of New Mountain Capital.
41 Articles
41 Articles
The Berkshire Eagle
TransMedics Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
ANDOVER, Mass., Aug. 1, 2025 /PRNewswire/ -- TransMedics Group, Inc. ("TransMedics") (Nasdaq: TMDX), a medical technology company that is transforming organ transplant therapy for patients with end-stage lung, heart, and liver failure, today announced that on July 28, 2025, TransMedics…
Inside Halton
Xenon Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
VANCOUVER, British Columbia and BOSTON, Aug. 01, 2025 (GLOBE NEWSWIRE) -- Xenon Pharmaceuticals Inc. (Nasdaq: XENE), a neuroscience-focused biopharmaceutical company dedicated to discovering, developing, and delivering life-changing therapeutics for patients in need, today announced equity inducement grants to six new…
Solid Biosciences Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
CHARLESTOWN, Mass., Aug. 01, 2025 (GLOBE NEWSWIRE) -- Solid Biosciences Inc. (Nasdaq: SLDB) (the 'Company”), a life sciences company developing precision genetic medicines for neuromuscular and cardiac diseases, today announced grants of 55,450 restricted stock units ('RSUs”) to four newly hired employees.
Coverage Details
Bias Distribution
- 45% of the sources are Center
Factuality
To view factuality data please Upgrade to Premium
